While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the research in chronic lymphocytic leukemia (CLL) is somewhat behind. In this video, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, gives an overview of the current data, explaining how CAR T-cell therapy appears to be less effective in CLL than in other diseases. He discusses how their potency in this disease might be improved, potentially via the addition of ibrutinib, and highlights three upcoming clinical trials in the field, which might be the turning point for this therapy in CLL.
CAR T-cells in CLL: the current landscape
